CTOs on the Move

Neighborhood Health Plan

www.nhp.org

 
Neighborhood Health Plan is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.nhp.org
  • 253 Summer St Fl 5
    Boston, MA USA 02210
  • Phone: 617.772.5500

Executives

Name Title Contact Details

Similar Companies

vision orlando inc

vision orlando inc is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dava Pharmaceuticals

Dava Pharmaceuticals is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Fort Lee, NJ. To find more information about Dava Pharmaceuticals, please visit www.davapharma.com

Receivable Solutions

Receivable Solutions is a national provider of revenue cycle management (“RCM”) services to hospitals and health systems. Through its client-focused culture, RSi delivers accounts receivable management and revenue cycle outsourcing services to accelerate provider cash flow, improve operating efficiencies and enhance profitability without sacrificing patient experience. The Company`s solutions span the full RCM continuum, providing both point solutions to address specific client challenges and full end-to-end RCM outsourcing. RSi was founded in 1999 and is headquartered in Columbia, South Carolina.

MDI Healthcare Solutions

MDI Healthcare Solutions is a Ponte Vedra, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cleveland Biolabs

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and an immunotherapy for oncology and other indications. We have additional pipeline product candidates in various stages of development.